Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
Tony Mira: Analyzing Anesthesiologists’ Investments in ASCs
Mylan’s Generic Anesthesia Drug Approved by FDA
Mission Hospital Renews Partnership With Asheville Anesthesia Associates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
